Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CLL 2022 | Combining BTK and BCL-2 inhibitors for the treatment of CLL

John Allan • 16 Mar 2022
ESH CLL 2022
Chronic Lymphocytic Leukemia Leukemia

John Allan, MD, Weill Cornell Medicine, New York, NY, highlights some important points from his presentation at ESH CLL 2022, which focused on combining Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors in the treatment of chronic lymphocytic leukemia (CLL). Dr Allan briefly discusses the topics covered in this presentation, including clinical trial data, safety and efficacy of these combinations, and more. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.

Disclosures

(Consultancy: Abbvie, AstraZenenca, BeiGene, Genentech, Janssen, Pharmacyclics) Research Genentech, Janssen

More from John Allan

2:43
Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax
John Allan • 12 Oct 2023
3:15
BruVenG trial: zanubrutinib and venetoclax, with obinutuzumab consolidation following MRD-positivity
John Allan • 12 Oct 2023
1:19
CLL treatment: a look into the future
John Allan • 16 Mar 2022
2:07
Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation
John Allan • 16 Mar 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals